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IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. The
disease generally runs an indolent course but may lead to ESRD in 20–30% of patients in
20 years or more after diagnosis. Patients with IgA nephropathy are ideal candidates for
renal transplant because they are generally relatively young and with few comorbidities.
Their graft survival is better or comparable to that of controls at 10 years, though few
data are available after 10 years of follow-up. Recurrence of the original disease in the
graft is a well-known complication of transplant in IgAN and is a significant cause of
deterioration of graft function. Recurrent IgAN rarely manifests clinically before 3 years
post transplantation. Recurrence rate is estimated to be around 30% with considerable
differences among different series. Despite these factors there is no certain recurrence
predictor, young age at renal transplant, rapid progression of the original disease and
higher levels of circulating galactose-deficient IgA1 and IgA-IgG immune complexes are
all associated with a higher rate of recurrence. Which pathogenetic mechanisms are
responsible for the progression of the recurrence to graft function deterioration, and
what therapy can prevent or slow down the progression of the disease in the graft,
are open questions. The aim of this review is to describe the clinical outcome of renal
transplantation in IgA patients with attention to the rate and the predictors of recurrence
and to discuss the available therapeutic options for the management of recurrence.
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INTRODUCTION
Glomerulonephritis (GN) is one of the most common diseases responsible for ESRD in the renal
registries worldwide with an incidence ranging from 10.5 to 38.2% and a prevalence from 17.6 to
53.5% (1). In Australia, in the period between 2010 and 2013, IgAN was responsible for 16% of all
incidents ESRD (2). Kidney transplantation is the best therapeutic option for IgAN patients. They
have greater access to kidney transplant compared to patients with other kidney diseases because
they are generally young and with few comorbidities. In the United States, between 2007 and 2011,
the proportion of patients who received a kidney transplant within 1 year was 30.2% for IgAN
compared to 2.4% for those with diabetes (3).
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IgAN frequently recurs in the graft. Owing to the progressive
improvement of graft survival resulting from reduced incidence
of acute rejection, the number of patients potentially exposed
to recurrence has increased. The incidence of IgAN recurrence
is not clearly estimated; it is reported to range from 9 to 53%
(4, 5), but the incidence increases if we consider only patients
submitted to graft biopsy. Several reasons can account for this
large discrepancy. The variable indication to graft biopsy in
the different centers is one of the reasons. The rate of IgAN
recurrence is higher in studies in which protocol biopsies are
performed (5) in comparison to studies that reported graft
biopsies done for clinical reasons only (6, 7) and in Registry
analysis (4). As a matter of fact, recurrences of IgAN can
be “histological only” when diagnosed on protocol biopsies
in asymptomatic patients; or “clinical,” when associated with
urinary abnormalities and/or graft dysfunction. The duration
of post-transplant follow-up is another important factor for
the development of recurrence of IgAN because the rate of
recurrence increases as the time from transplant lengthens
(5). It is unclear if recurrence is (8–10) or is not (11,
12) more frequent in transplants using related donors but
this uncertainty does not preclude consideration of living
donation in IgAN.
Recurrent glomerulonephritis is a significant cause of graft
loss in transplant patients. Largest registry studies of Australia
andNewZealand reported that IgAN recurrence was a significant
cause of graft loss, third only to chronic allograft nephropathy
and death with graft function. At 10 years the rate of graft loss for
IgAN was similar to that of other forms of glomerulonephritis
and to those of other causes of ESRD (13, 14). Outcomes after 10
years have been insufficiently studied in registry studies to draw
firm conclusions, although results of a recent European Registry
analysis (15) and some cohort studies suggested increasing graft
loss after 10 years (16, 17).
IgA NEPHROPATHY IN THE
NATIVE KIDNEY
Among primary chronic glomerular diseases, IgA nephropathy
(IgAN) is the most prevalent worldwide (18). The clinical
presentation is highly heterogeneous ranging from macroscopic
hematuria with or without acute renal dysfunction during
an infective episode and microscopic hematuria, isolated, or
associated with proteinuria and hypertension. The diagnosis of
certainty requires a renal biopsy, which shows the presence of
dominant or codominant diffuse mesangial deposition of IgA
which, in most cases, are aberrantly glycosylated. The mesangial
IgA is exclusively of the IgA1 subclass and is deficient in
galactose (19).
The pathogenesis of the disease is not completely clarified.
Recent genome-wide association studies have identified multiple
susceptibility loci for IgAN implicating independent defects
in adaptive and innate immunity, and alternative complement
pathways that potentially influence the different pathogenetic
steps of the disease (20). By combining genetic and biochemical
data, at least four processes seem to contribute to the
development of the disease. Based on the available knowledge,
there is in IgAN a primary, inherited defect that leads to
preferential production of IgA1 with galactose-deficient O-
glycans in the hinge-region (21). In the presence of inheritance
of permissive MHC haplotypes, IgA1 deficient in galactose
elicits the production of antiglycan autoantibodies, that lead
to the formation and subsequent glomerular deposition of
immune complexes. In particular IgA based activation of
alternative complement pathway play a critical role in the IgAN
pathogenesis and C3 is frequently involved in the formation of
circulating immune deposits inducing mesangial stress, podocyte
damages (22), and progressive deterioration of kidney function
(23). On this basis IgAN is classified as an autoimmune
disease (24). Recent attempts to characterize mediators of this
response have focused on facilitators of B-cell differentiation
and proliferation (25). The B cell activation factor of TNF
family (BAFF) and a proliferation-inducing ligand (APRIL)
has been indicated as modulating factors of B cell in the
IgA pathogenesis by reducing both IgA serum levels and IgA
glomerular deposition. Thesemolecules may represent intriguing
therapeutic targets for new IgAN treatments (26).
The disease generally runs an indolent course with a 10-
year renal survival rate of about 90% among adults (27) and
children (28) with normal renal function at diagnosis. However,
20–30% of patients develop end stage renal disease (ESRD) after
20 years or more follow-up (29), and need chronic dialysis or
renal transplantation.
Proteinuria of at least 1 g/day, decreased estimated glomerular
filtration rate (eGFR) at diagnosis and uncontrolled arterial
hypertension are the clinical risk factors for the progression to
ESRD (30). The Oxford classification of histological features of
IgAN in the native kidney, that is based on the semiquantitative
score of four histological features (mesangial hypercellularity,
segmental glomerulosclerosis, endocapillary hypercellularity,
and tubular atrophy/interstitial fibrosis), was found to be
associated with increased risk of eGFR loss independent of
clinical variables (31).
HISTOLOGICAL FEATURES OF IgAN
RECURRENCE IN KIDNEY TRANSPLANT
Biopsy is mandatory not only to diagnose the disease in
the native kidney, but also to identify and characterize graft
recurrence of IgAN in the kidney graft. For this reason, the
biopsy policies of the different centers and the techniques of
histological evaluation have an important role in the definition
of presence, frequency, and type of recurrence. Recurrence can
be histological only, characterized by mesangial IgA with or
without mesangial proliferation in the absence or presence of
mild clinical manifestations. Ortiz et al. (32) evaluated the
incidence of IgAN recurrence through protocol biopsies in 65
patients and found that the histological recurrence of IgAN
can be recognized in almost one-third of patients within 2
years from transplantation. These results confirm those of a
previous study with protocol biopsies that reported a 53%
recurrence rate in 32 IgAN transplanted patients. Most of
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these patients did not have clinical signs of recurrence (5).
The clinical value and the outcome of silent recurrent IgA
deposits is not completely clarified. In some cases the disease
progressed to overt clinical IgAN recurrence, (33) in others, IgA
deposits disappeared in subsequent biopsies (34). The possibility
of disappearance of IgA deposits from the kidney was also
demonstrated in repeated renal biopsies of native IgAN (35).
The demonstration that some apparently normal donors (living
or deceased) may have latent IgA deposits in the kidney, raises
the possibility that some histological recurrence can have such
origin (36). Actually, when allografts with latent mesangial IgA
deposits were transplanted in non IgA patients, the IgA was
rapidly cleared by the recipients as demonstrated in follow-up
biopsies (37). The transformation of the histological recurrence
in clinical recurrence could be mediated by the activation of
accessory factors such as activation of complement and cytokines
production (38). However, based on the few available data about
the clinical value of “histological” recurrence and the lack of an
effective therapy, protocol biopsies in renal transplant patients
with IgAN are not recommended unless steroid withdrawal is
considered. The histological findings recorded at graft biopsy
performed for clinical reasons, are not different from those of the
original disease. In graft biopsy the diagnosis can be complicated
by the simultaneous presence of other glomerular or vascular
lesions secondary to acute or chronic graft rejections. In these
cases, not only light microscopy and immunofluorescence, but
also electron microscopy is needed to clearly define the possible
association of two different diseases. In addition tomesangial IgA
immunodeposits at immunofluorescence, mesangial proliferative
glomerulonephritis is the typical histological pattern at light
microscopy in IgAN recurrence with, in a minority of cases,
features of glomerular cellular crescents. In a cohort of 71 IgAN
transplanted patients, cellular or fibrocellular crescents were
demonstrated in 14.1% of graft biopsies and were associated with
a higher degree of interstitial inflammation and with a significant
worse graft survival (39).
Some studies suggest that, the Oxford classification of
histological features of IgAN in the native kidney, (31) applied
to biopsies of recurrent IgAN has prognostic value for graft
failure (40, 41). Based on these results the evaluation of the
Oxford classification score, should be performed in all cases of
IgAN recurrence.
CLINICAL MANIFESTATIONS OF IgAN
RECURRENCE IN KIDNEY TRANSPLANT
In the majority of studies the IgAN recurrence is diagnosed
in graft biopsies performed for clinical reasons. The clinical
presentation and the outcome of recurrences is extremely
variable. Hematuria, the hallmark of IgAN in the native kidney,
is not a reliable manifestation in recurrence as it was not present
in 64% of cases diagnosed on protocol biopsies (32). Even in
biopsies performed for clinical reasons hematuria is not the
rule. In our cohort of 190 IgAN transplanted patients, the
43 recurrences presented with isolated microscopic haematuria
in 5, isolated proteinuria in 8, microscopic haematuria and
proteinuria in 12, isolated increase in plasma creatinine in 4,
increase in plasma creatinine associated with haematuria or
haematuria and proteinuria in the other 13 cases. In the four
patients with an isolated increase in serum creatinine proteinuria
and haematuria developed later, instead in seven patients all
the urinary abnormalities regressed during the follow-up (17).
Altogether in about one quarter of our patients, microscopic
haematuria, the hallmark of IgAN in the native kidney, was not
present at diagnosis of recurrences. This underlines that graft
biopsy is essential to ensure the correct diagnosis.
INCIDENCE OF IgAN RECURRENCE IN
KIDNEY TRANSPLANT
The reported incidence of IgAN recurrence in biopsies
performed for clinical reasons is around 30% but with a range
of 9–53% among the different series if we consider protocol
and clinical biopsies (Table 1). This large discrepancy can be
attributed to several reasons in addition to the above reported
different biopsy policies and techniques of histological evaluation
in the different centers. The different racial and geographical
distributions of IgAN may influence the rate of recurrence.
The presence of IgA deposits in donated kidneys, frequently
observed in Japanese series (36) was hypothesized to increase
the probability of recurrence (47). The rate of recurrence can
be underestimated if all patients who receive a renal transplant
do not have a histological diagnosis of the original disease, or
if the follow-up after transplant is too short. Recurrence rate
reported in the ANZDATA registry for IgAN at 5 and at 10
years were, respectively 5.4% (4.3–6.5) and 10.8% (9.2–12.5%)
(4). These data suggest that, recurrence of IgAN is apparently
a time dependent event; the longer the follow-up, the higher
the probability of recurrence. The incidence of IgAN recurrence
can be underestimated if all patients with deterioration of renal
function or with proteinuria are not submitted to graft biopsy.
In the absence of graft biopsy, it is possible that some graft
losses classified as chronic allograft nephropathy could be cases
of unrecognized recurrence of IgAN (13).
The rate of graft loss due to recurrence is reported to
range from 1.3 (46) to 17% (5). However, the attribution of
graft loss to the recurrence is not easy due to the possible
presence of concomitant lesions due to acute or chronic graft
rejections or to calcineurin inhibitors toxicity. This is particularly
true if graft biopsy is not available close to the graft function
deterioration (56).
PREDICTORS OF IgAN RECURRENCE IN
KIDNEY TRANSPLANT
Analysis of risk factors for IgAN recurrence have not provided
consistent results. Young age at renal transplantation, male
gender, and rapidly progressive course of the original disease
before transplantation were associated with a higher risk of
recurrence in some studies (10, 11, 13, 57). Avesare et al.
(54) reevaluated the clinical and biopsy features of native
kidney in 62 IgAN patients who received a transplant at
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TABLE 1 | Main studies on IgA nephropathy recurrence.
Year of
publication
Authors Study design Number of
patients
IgAN
recurrence
rate (%)
Time to
recurrence
(years)
Graft losses
due to
recurrence
(%)
Follow–up
(years)
Protocol or
clinical
biopsies
1998 Matsugami et al. (42) Retrospective 49 24.5 – – – Protocol
2007 Mousson et al. (43) Retrospective 42 52.4 – 4.7 8.9 Protocol
2012 Ortiz F et al. (32) Retrospective 65 32.3 6.9 months 3 4.67 Protocol
1994 Odum et al. (5) Prospective–
retrospective
46 53
36.9
3.8 17.2 3–183
months
Protocol/
Clinical
1996 Kessler et al. (33) Retrospective 84 15.5 3.2 4.8 5.7 Clinical
1997 Frohnert et al. (34) Retrospective 53 26.4 – 18.8 – Clinical
1997 Ohmacht et al. (44) Retrospective 61 22.9 5.4 16.4 – Clinical
1998 Bumgardner et al. (44) Retrospective 61 29.5 2.6 9.8 5.1 Clinical
1999 Freese et al. (6) Retrospective 104 12.5 6 5.8 5 Clinical
2000 Stack et al. (45) Retrospective 44 11.4 – – – Clinical
2001 Kim et al. (12) Retrospective 90 21.1 – 2.2 – Clinical
2001 Wang et al. (9) Retrospective 48 29.2 4.3 8.3 4.3 Clinical
2001 Ponticelli C et al. (11) Retrospective 106 34.9 4.3 3.8 5.9 10 Protocol
47 Clinical
2001 Andresdottir et al. (46) Retrospective 79 21.5 13–145 months 1.3 5.6 Clinical
2003 Choy et al. (16) Retrospective 75 18.7 5.6 4 – Clinical
2005 Moriyama T et al. (47) Retrospective 49 26.5 3.25 10 – Clinical
2005 Chandrakantan et al. (7) Retrospective 152 13.1 3.6 7.8 – Clinical
2005 Soler et al. (48) Retrospective 37 19.4 4.1 8.1 – Clinical
2009 Kennoki et al. (49) Retrospective 405 16 – – 1 Protocol
2009 Han et al. (10) Retrospective 221 19.9 – 7.7 5.9 Clinical
2012 Kamal et al. (50) Retrospective 142 17.6 – 7 6.6 Clinical
2013 Moroni et al. (51) Retrospective 190 22.1 3.7 6.3 9.4 Clinical
2014 Von Visger et al. (52) Retrospective 124 22 – – 6.8 Clinical
2017 Berthoux et al. (53) Retrospective 96 35.4 5.8 12.3 12.4 Clinical
2017 Avasareet al. (54) Retrospective 62 22.5 2.75 – – Clinical
2018 Garnier et al. (55) Retrospective 67 20.8 3.13 – 5.9 Clinical
2018 Jiang et al. (4) Retrospective 2,393 9.9 4.63 10 Clinical
Columbia University Medical Center from 2001 to 2012.
They found that younger age at onset of IgAN and greater
burden of crescents on native biopsy predicted recurrence
after transplant.
Garnier et al. (55) found that serum IgA levels 6 months post-
transplant was a risk factor of IgAN recurrence, independently
of age, and serum creatinine. This was particularly true in
patients who had serum IgA levels above 222.5 mg/dL at month
6 post-transplant.
Berthoux et al. (53) tested serum autoantibodies specific for
galactose deficient-IgA1 at time of transplant or at time of
native-kidney diagnosis in 96 first renal transplant recipients
with IgAN. This study demonstrated that normalized serum
levels of galactose deficient -IgA1–specific IgG autoantibody
was an independent risk factor for recurrence of the disease
in the allograft. This was particularly true for the earlier
recurrences: 75% of events occurring before 8.79 years after
transplantation (53).
Another unsolved question is whether living related donor
kidneys have a higher risk of recurrence than kidneys from non-
related donors. Some studies have failed to detect a significant
difference (7, 11, 12, 34, 58) while others noted more frequent
recurrences in grafts from living related donors (6, 9, 10). A
review of the Australia-New Zealand registry data reported that
IgAN recurrence was significantly more frequent in zero HLA
mismatched living donor grafts (59). However, these results
should be interpreted with caution because several details are
lacking in retrospective reviews of registry data.
The risk of recurrence in the second graft in
glomerulonephritis patients who lost the first graft for recurrence
was investigated in 7,236 patients of the ANZDATA transplant
registry. No increased risk of further recurrence in a subsequent
graft was demonstrated for IgAN patients (4). This result is
in contrast with previous small reports which suggested an
increased risk of recurrences in patients with IgAN who lost the
first graft for recurrence (6, 44, 60)
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Current immunosuppressive agents used in transplantation
do not seem to reduce IgAN recurrence in the allograft.
Retrospective data from a single center suggests that
induction therapy with antithymocyte globulin prevents
the development of IgAN recurrence (57). Von Visger et
al reported a significantly higher rate of IgA recurrence in
patients maintained on steroid-free immunosuppression
in comparison to those who received steroid-based
immunosuppression (52).
PATIENT AND RENAL SURVIVAL OF
KIDNEY TRANSPLANT IN IgAN PATIENTS
Outcome of patients and graft survival in IgAN can be obtained
from Registry analysis and from single centers observational
studies. In comparison to single center studies, Registry analysis
have the advantage of reporting data on a high number
of patients but, some outcomes, such as causes of allograft
failure, and incidence of recurrence are not accurately measured
or are underestimated due to the different policies of the
included centers. Single center retrospective studies provide
more detailed information on different aspects of the disease
in IgA transplanted patients but have low power in predicting
the outcome.
The survival of transplanted patients with IgAN seems to
be comparable or slightly better with that of recipients with
other renal diseases both in Registry analysis and in single
center studies. Among 32,131 patients with glomerulonephritis
transplanted in theUnited States between 1996 and 2011, patients
with IgAN had the lowest mortality rates (10% mortality at 10
years) in comparison to other glomerulonephritis forms and a
slightly better survival than that of transplanted patients with
adult polycystic kidney disease (APKD) (61). UK Renal Registry
data, that analyzed patient survival in 2,975 incident patients with
primary glomerulonephritis in comparison to 1,775 transplanted
APKD patients who received a renal transplant between 1997 and
2009, reported unadjusted 10-year patient survival of 80.7% for
APKD and 85.6% for IgAN (62).
Instead, the results of graft survival in patients with
IgAN have been differently estimated across different countries
and populations. The UNOS/OPTN database, in patients
transplanted between 1999 and 2008, reported, in patients
stratified for donor type (living vs. deceased) that at multivariable
regression analysis the adjusted HR for death-censored allograft
survival was not significantly different between IgAN and
non-IgAN patients (63). Data from the European ERA-
EDTA registry reported that the risk of death-adjusted graft
failure for IgAN patients was not different from that of
APKD until 10 years after transplant, thereafter the risk of
graft loss was greater in IgAN (15). In addition, this study
demonstrated that living related transplants in IgAN patients
had lower risk of death-adjusted graft failure compared with
deceased related transplants. The same lower death-adjusted
graft survival of IgAN patients in comparison to APKD was
reported by a largest study of transplanted patients in the
United States (61).
The results concerning graft survival of IgAN patients
reported by the single center studies are equally contrasting and
depend partly on the length of the observation.
Some investigators reported a more favorable graft survival
in IgAN patients than in other transplant recipients (64, 65),
but other authors found similar results in an IgAN group than
in non-IgAN transplant patients (48, 50, 58, 66). In particular,
during the first 5 years after transplantation allograft survival
for primary IgAN patients seems to be better than that of
recipients with other primary renal diseases (12, 46, 64, 66, 67).
Based on these short-term results, the recurrence of IgAN was
considered to have little or no impact on graft function or on
patient outcome (5, 68). At 10 years, graft survival of IgAN
patients became comparable to that of recipients with other renal
diseases (11, 12).
Choy et al. (16) found that the graft survival of up to 10 years
was worse in IgAN patients than in controls, the two survival
curves crossover at around 12 years. Our results are in agreement
with actuarial death censored graft survival rates at 15 years of
62.6% in IgAN patients significantly worse than the 72.4% in
the control group. In our cohort, the difference between the two
survival curves become significant after the 15th year. When we
separately evaluated the outcome of patients with and without
recurrence we found that death censored graft survival at 15
years was 51.2% in the recurrent patients and significantly better
(68.3%) in the non-recurrent recipients. Finally, graft survival in
non-recurrent patients was not different from that of controls
(17). The worst graft survival in the long-term of recurrent in
comparison to non-recurrent IgAN patients was confirmed both
in the recent report of the ANZDATA Registry (4) and by a
retrospective study in 221 Korean recipients. In this study around
50% of patients received a graft from living related donors. Ten-
years graft survival was 61% in recurrent IgAN group vs. 85.1%
in non-recurrent patients (10).
It is well-known, that recurrence of glomerulonephritis is
the third most frequent cause of allograft loss at 10 years,
after chronic rejection and death with a functioning graft
(13, 69). Based on these recent results, it seems that also for
IgAN, the graft recurrence represents a substantial risk factor
for graft failure in the very long-term as hypothesized by
Ponticelli and Glassock (70). The introduction of new and more
effective immunosuppressive agents has reduced graft loss by
decreasing the incidence of acute rejection and of interstitial
fibrosis and tubular atrophy. In this scenario, the recurrence of
glomerulonephritis became progressively more frequent and can
be a significant cause of graft loss in clinical practice. Mulay
et al. reported that, after adjusting for important covariates,
the use of cyclosporine, tacrolimus, azathioprine, mycophenolate
mofetil, sirolimus, or prednisone does not prevent graft
failure due to recurrent glomerulonephritis, including IgAN.
However, any change in immunosuppression during follow-
up was independently associated with graft loss due to
recurrence (71).
Probably, old and short-term studies failed to detect a clinical
impact of recurrent disease because, it is rare that the function of
a graft with IgAN recurrence deteriorates during the first years
after transplantation (67).
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TREATMENT OF GRAFT RECURRENCES
OF IgAN PATIENTS
No universally accepted guidelines for the treatment of
recurrence of IgAN in renal transplant are currently available.
The goal of the therapy should be to prevent recurrence of IgAN.
Clayton et al. (14) suggested that steroid withdrawal may
increase graft loss risk because of recurrence of IgAN. These
results were confirmed in two subsequent studies (72, 73). In a
retrospective analysis of the UNOS/OPTN database that included
9,690 IgAN adults who received their first kidney transplant
between 2000 and 2014, early steroid-withdrawal was associated
with an increased risk of recurrence at multivariate analysis (72).
At present treatment should aim to reduce proteinuria,
to optimize blood pressure and to reduce inflammation as
suggested by the KDIGO Transplant guidelines (74). The
institution of good supportive therapy in particular the use
of angiotensin converting enzyme inhibitors or angiotensin II
receptor blocker in patients with proteinuria higher than 0.5
g/day is recommended based on good results reported in some
studies (75, 76). Careful blood pressure control, particularly
in patients with proteinuria > than 1 g/day, seems to be
important to preserve graft function. However, it is important
to consider that the use of these drugs in renal transplant
may cause significant decreases in glomerular filtration rate and
hematocrit (77). Studies from Japan report favorable outcomes
after tonsillectomy in patients with recurrent IgAN (49, 78, 79)
but these results need to be confirmed in different ethnicities.
In the few cases of recurrent IgAN with rapid progressive
renal insufficiency and crescents at biopsy, a rescue treatment
with high-dose corticosteroids with cyclophosphamide, and or
plasmapheresis may be attempted, although the results are
usually poor. A promising therapeutic option is represented
by drugs which target directly the intestinal mucosa, such
as budesonide. Fellström et al. reported a reduction of
proteinuria and a stabilization of renal function after budesonide
administration in IgAN patients, suggesting a possible role of
this drug also in patients with IgAN recurrence after kidney
transplant (80).
CONCLUSIONS
Despite the high rate of recurrence and its potential negative
impact on graft survival, renal transplant is the best choice
for patients with ESRD secondary to IgAN. In our experience,
recurrence of IgAN significantly reduced from 1981 to 2010 and
in particular, recurrences occurred less frequently in transplants
performed during the decade 2000–2010 (17). These results
and the apparent reduction in graft loss from recurrent IgAN
reported by Mulay et al. (71) and by Clayton et al. (14) in recent
years may portend a progressive improvement of prognosis of
renal transplant in IgAN patients in the near future. Better
understanding of pathogenesis of the disease may enable more
“specific” therapy. A large prospective multicenter randomized
controlled trial with a long follow-up to evaluate interventions for
recurrent IgA would be welcome and of importance in helping
clinicians and patients.
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